Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 16 05 2023
accepted: 20 07 2023
revised: 19 07 2023
medline: 23 10 2023
pubmed: 8 8 2023
entrez: 8 8 2023
Statut: ppublish

Résumé

Parkinson's disease (PD) diagnosis is still vulnerable to bias, and a definitive diagnosis often relies on post-mortem neuropathological diagnosis. In this regard, alpha-synuclein (αsyn)-specific in vivo biomarkers remain a critical unmet need, based on its relevance in the neuropathology. Specifically, content changes in αsyn species such as total (tot-αsyn), oligomeric (o-αsyn), and phosphorylated (p-αsyn) within the cerebrospinal fluid (CSF) and peripheral fluids (i.e., blood and saliva) have been proposed as PD biomarkers possibly reflecting the neuropathological outcome. Here, we measured the p-αsyn levels in the saliva from 15 PD patients along with tot-αsyn, o-αsyn and their ratios, and compared the results with those from 23 healthy subjects (HS), matched per age and sex. We also calculated the optimal cutoff values for different αsyn species to provide information about their capability to discriminate PD from HS. We found that p-αsyn was the most abundant alpha-synuclein species in the saliva. While p-αsyn concentration did not differ between PD and HS when adjusted for total salivary proteins, the ratio p-αsyn/tot-αsyn was largely lower in PD patients than in HS. Moreover, the concentration of o-αsyn was increased in the saliva of PD patients, and tot-αsyn did not differ between PD and HS. The ROC curves indicated that no single αsyn form or ratio could provide an accurate diagnosis of PD. On the other hand, the ratio of different items, namely p-αsyn/tot-αsyn and o-αsyn, yielded more satisfactory diagnostic accuracy, suggesting that the combined measure of different species in the saliva may show more promises as a diagnostic means for PD.

Identifiants

pubmed: 37552278
doi: 10.1007/s00415-023-11893-x
pii: 10.1007/s00415-023-11893-x
pmc: PMC10576686
doi:

Substances chimiques

alpha-Synuclein 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5613-5621

Subventions

Organisme : Regione Autonoma della Sardegna
ID : RASSR08834

Informations de copyright

© 2023. The Author(s).

Références

Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neuron. 2013 Sep 18;79(6):1044-66
pubmed: 24050397
Trends Neurosci. 2023 Feb;46(2):153-166
pubmed: 36567199
Sci Rep. 2016 Feb 16;6:20863
pubmed: 26878893
Parkinsonism Relat Disord. 2019 Nov;68:69-72
pubmed: 31621624
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
J Neuropathol Exp Neurol. 2003 Jun;62(6):644-54
pubmed: 12834109
EMBO J. 2009 Oct 21;28(20):3256-68
pubmed: 19745811
J Neuropathol Exp Neurol. 2013 Feb;72(2):130-6
pubmed: 23334596
Brain. 2011 Jul;134(Pt 7):e178
pubmed: 21349902
Sci Rep. 2013;3:2540
pubmed: 23985836
Front Neurol. 2020 Sep 17;11:1043
pubmed: 33041984
Mov Disord. 2016 Feb;31(2):152-60
pubmed: 26340605
Int J Mol Sci. 2020 Oct 28;21(21):
pubmed: 33126694
Exp Neurol. 2008 Oct;213(2):315-25
pubmed: 18625222
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9
pubmed: 21325059
Ann Clin Transl Neurol. 2019 Dec;6(12):2426-2436
pubmed: 31742923
Acta Neuropathol Commun. 2015 Jan 31;3:7
pubmed: 25637461
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28108534
Front Neurosci. 2019 Apr 18;13:381
pubmed: 31057362
Front Mol Neurosci. 2018 Feb 22;11:53
pubmed: 29520218
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Front Aging Neurosci. 2021 Jul 08;13:702639
pubmed: 34305577
Cranio. 2021 Jul;39(4):321-325
pubmed: 31296125
PLoS One. 2016 Mar 24;11(3):e0151156
pubmed: 27011009
Arch Neurol. 2008 Dec;65(12):1577-81
pubmed: 19064744
Neurology. 2012 Mar 6;78(10):696-701
pubmed: 22323748
Transl Neurodegener. 2019 May 15;8:15
pubmed: 31123587
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
N Am J Med Sci. 2014 Dec;6(12):633-7
pubmed: 25599051
J Parkinsons Dis. 2018;8(4):517-527
pubmed: 30248065
Mov Disord. 2019 Oct;34(10):1452-1463
pubmed: 31322768
Sci Transl Med. 2012 Feb 15;4(121):121ra20
pubmed: 22344688
Mov Disord. 2006 Jul;21(7):916-23
pubmed: 16547944
Parkinsonism Relat Disord. 2022 Nov;104:44-48
pubmed: 36228514
Brain. 2002 Apr;125(Pt 4):861-70
pubmed: 11912118
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Neurology. 2016 Feb 9;86(6):566-76
pubmed: 26764028
Parkinsonism Relat Disord. 2019 Jun;63:143-148
pubmed: 30796010
Neurodegener Dis. 2008;5(2):55-9
pubmed: 18182779
Brain Pathol. 2016 May;26(3):410-8
pubmed: 26940058
J Neurosci Methods. 2020 May 15;338:108685
pubmed: 32173400
FASEB J. 2011 Dec;25(12):4127-37
pubmed: 21865317
Acta Neuropathol. 2014 Nov;128(5):639-650
pubmed: 24997849
Neurology. 2014 Mar 11;82(10):858-64
pubmed: 24500652
Mov Disord. 2017 Oct;32(10):1389-1400
pubmed: 28880418

Auteurs

Fabrizio Angius (F)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Ignazia Mocci (I)

CNR Institute of Translational Pharmacology, Unit of Cagliari, Cagliari, Italy.

Tommaso Ercoli (T)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Francesco Loy (F)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Laura Fadda (L)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Maria Francesca Palmas (MF)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Giada Cannas (G)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Aldo Manzin (A)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Giovanni Defazio (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. giovanni.defazio@uniba.it.
Department of Translational Biomedicine and Neuroscience, Aldo Moro University of Bari, Bari, Italy. giovanni.defazio@uniba.it.

Anna R Carta (AR)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH